FLECAINIDE FLOXURIDINE
Neil Shear in Litt's Drug Eruptions & Reactions Manual, 2010
FLECAINIDE Trade names: Almarytm; Apocard; Corflene; Flecaine; Tabco; Tambocor (3M) Indications: Atrial fibrillation Category: Antiarrhythmic class 1c Half-life: 7-22 hours Clinically important, potentially hazardous interactions with: amisulpride, darifenacin, fosamprenavir, ritonavir, tipranavir
ARNICA
Neil Shear in Litt's Drug Eruption & Reaction Manual 25E, 2019
Family: Asteraceae; Compositae Scientific names: Arnica fulgens, Arnica montana, Arnica sororia Indications: Bruising, aches and sprains, insect bites, superficial phlebitis, diuretic, flavoring agent, found in hair tonic and shampoo Class: Immunomodulator Half-life: N/A Clinically important, potentially hazardous interactions with: none known Pregnancy category: N/A Skin Dermatitis [5] ARTEMETHER/ LUMEFANTRINE Trade name: Coartem (Novartis) Indications: Acute, uncomplicated malaria infections due to Plasmodium falciparum in patients of 5kg bodyweight and above Class: Antimalarial Half-life: ~2 hours (artemether); 3-6 days (lumefantrine) Clinically important, potentially hazardous interactions with: amiodarone, amitriptyline, amoxapine, antimalarials, antiretrovirals, arsenic, astemizole, atazanavir, atovaquone/proguanil, azithromycin, carbamazepine, ciprofloxacin, citalopram, clomipramine, conivaptan, CYP2D6 substrates, CYP3A4 inducers, inhibitors or substrates, darunavir, dasatinib, degarelix, delavirdine, disopyramide, dolasetron, duloxetine, flecainide, halofantrine, hormonal contraceptives, imipramine, indinavir, itraconazole, lapatinib, levofloxacin, levomepromazine, lopinavir, mefloquine, moxifloxacin, nelfinavir, norfloxacin, ofloxacin, paroxetine hydrochloride, pazopanib, phenytoin, pimozide, procainamide, quinidine, quinine, rifampin, risperidone, sotalol, St John’s wort, telavancin, telithromycin, terfenadine, tipranavir, venlafaxine, voriconazole, vorinostat, ziprasidone, zuclopenthixol Pregnancy category: C Important contra-indications noted in the prescribing guidelines for: nursing mothers; pediatric patients Note: Artemether/Lumefantrine tablets should not be used to treat severe malaria or to prevent malaria.
ELVITEGRAVIR /
Neil Shear in Litt's Drug Eruptions and Reactions Manual, 2013
ELVITEGRAVIR / COBICISTAT / EMTRICITABINE / TENOFOVIR Trade name: Stribild (Gilead) Indications: HIV-1 infection Class: Antiretroviral, Integrase strand transfer inhibitor, Nucleoside analog reverse transcriptase inhibitor, Nucleotide analog reverse transcriptase inhibitor, Pharmacokinetic enhancer Half-life: 12.9 hours (elvitegravir); 3.5 hours (cobicistat) Clinically important, potentially hazardous interactions with: acyclovir, adefovir, amiodarone, amitriptyline, amlodipine, antacids, antirarrhythmics, antiretrovirals, atorvastatin, bepridil, beta blockers, bosentan, bupropion, buspirone, calcium channel blockers, carbamazepine, cidofovir, clarithromycin, clonazepam, clorazepate, colchicine, cyclosporine, desipramine, dexamethasone, diazepam, digoxin, diltiazem, disopyramide, drugs affecting renal function, emtricitabine, estazolam, ethosuximide, felodipine, flecainide, flurazepam, fluticasone, ganciclovir, hormonal contraceptives, imipramine, immunosuppressants, itraconazole, ketoconazole, lamivudine, lidocaine, metoprolol, mexiletine, midazolam, neuroleptics, nicardipine, nifedipine, non-nucleoside reverse transcriptase inhibitors, nortriptyline, oxcarbazepine, paroxetine, perphenazine, phenobarbital, phenytoin, propafenone, protease inhibitors, quinidine, rifabutin, rifapentine, risperidone, ritonavir, salmeterol, sedatives / hypnotics, sildenafil, sirolimus, SSRIs, tacrolimus, tadalafil, telithromycin, tenofovir, thioridazine, timolol, trazodone, tricyclic antidepressants, valacyclovir, valganciclovir, vardenafil, verapamil, voriconazole, warfarin, zolpidem Pregnancy category: B Note: See also separate profiles for emtricitabine and tenofovir.
Polymorphism and solvates of flecainide base
Published in Pharmaceutical Development and Technology, 2014
K. Veldre, Z. Eglīte, A. Actiņš, A. Zvirgzdiņš, L. Rozenberga, E. Tamanis
Flecainide base is pharmaceutically active substance used for production of flecainide acetate which is known in market as Tambacor, Almarytm, Apocard, Ecrinal or Flecaine. It is determined that flecainide base forms four polymorphic forms abbreviated as Ib, IIb, IIIb and IVb. Flecainide base form Ib is thermodynamically stable form at laboratory temperature while form IIIb is stable at higher temperatures. Flecainide form Ib absorbs water in its structure between layers and forms non-stoichiometric hydrate. Flecainide base binds with organic solvents and form monosolvates. Flecainide base form Ib crystallizes in orthorhombic crystals with lattice parameters a = 27.88 Å, b = 13.78 Å, c = 9.98 Å and two independent molecules in unit cell (Z′ = 2; Z = 8). Molecule arrangement in flecainide base form Ib structure is not dense and it forms a channel-type structure, where molecules of water and alcohols are placed.
Flecainide toxicity in renal failure
Published in Baylor University Medical Center Proceedings, 2018
Rogin Subedi, Ryan K. Dean, Arbind Chaudhary, Tamas Szombathy
Flecainide, a class Ic antiarrhythmic, is used for the prevention of paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation/flutter, and sustained ventricular tachycardia. Flecainide is primarily metabolized by the liver and to a lesser extent (30%) is excreted unchanged in the kidney. We present a case of flecainide toxicity in the setting of renal impairment that was successfully treated with intravenous sodium bicarbonate.
Effect of flecainide on the extension and localization of complex fractionated electrogram during atrial fibrillation
Published in Scandinavian Cardiovascular Journal, 2015
Alessandro De Bortoli, Li-Bin Shi, Yu-Chuan Wang, Per Ivar Hoff, Eivind Solheim, Ole-Jørgen Ohm, Jian Chen
Aims. Complex fractionated electrogram (CFE) ablation in addition to pulmonary vein isolation is an accepted strategy for the treatment of non-paroxysmal atrial fibrillation (AF). We sought to determine the effect of flecainide on the distribution and extension of CFE areas. Methods. Twenty-three non-paroxysmal AF patients were enrolled in this prospective study. A first CFE map was obtained under baseline conditions by sampling 5 s of continuous recording from the distal electrodes of the ablation catheter. Intravenous flecainide (1 mg/kg) was administered over 10 min and followed by 30-min observation time. A second CFE map was obtained with the same modalities. CFE-mean values, CFE areas, and atrial electrogram amplitude were retrieved from the electro-anatomical mapping system (Ensite NavX). Results. After flecainide administration, CFE-mean values increased (111.5 ± 55.3 vs. 132.3 ± 65.0 ms, p < 0.001) with a decrease of CFE area (32.9%) in all patients. Atrial electrogram amplitude decreased significantly (0.30 ± 0.31 vs. 0.25 ± 0.20 mV, p < 0.001). We observed 80.9% preservation of CFE areas. A CFE mean of 78 ms was the best cutoff for predicting stable CFE areas. Conclusions. Flecainide reduces the extension of CFE areas while preserving their spatial localization. A CFE-mean value
Related Knowledge Centers
- Antiarrhythmic Agent
- Arrhythmia
- Arrhythmias
- Atrial Fibrillation
- Heart
- Tachycardias
- Piperidines